New York Life Investment Management LLC Has $959,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

New York Life Investment Management LLC boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,942 shares of the biotechnology company’s stock after acquiring an additional 166 shares during the quarter. New York Life Investment Management LLC’s holdings in Sarepta Therapeutics were worth $959,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Sarepta Therapeutics by 5.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,865 shares of the biotechnology company’s stock valued at $11,621,000 after purchasing an additional 4,763 shares during the period. TD Asset Management Inc lifted its stake in Sarepta Therapeutics by 377.7% in the third quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock valued at $24,805,000 after buying an additional 161,788 shares during the period. Eagle Health Investments LP boosted its holdings in Sarepta Therapeutics by 79.0% during the third quarter. Eagle Health Investments LP now owns 174,212 shares of the biotechnology company’s stock worth $21,118,000 after buying an additional 76,872 shares during the last quarter. Hudson Capital Management LLC acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth about $206,000. Finally, Assetmark Inc. increased its stake in shares of Sarepta Therapeutics by 17.1% in the 3rd quarter. Assetmark Inc. now owns 3,816 shares of the biotechnology company’s stock valued at $463,000 after acquiring an additional 558 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

SRPT has been the subject of several recent analyst reports. Citigroup upped their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Barclays lifted their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. UBS Group lifted their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $166.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, May 2nd. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $160.60.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $136.04 on Wednesday. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $159.89. The company’s fifty day simple moving average is $125.47 and its 200-day simple moving average is $111.07. The firm has a market cap of $12.86 billion, a PE ratio of 1,236.73 and a beta of 0.95. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.44) EPS. Equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.23 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,731 shares of company stock valued at $3,248,319. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.